Inclisiran dramatically lowered PCSK9 and LDL in ORION-1 trial | ACC


  • Conference reports - RSi Communications
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Inclisiran dramatically lowered PCSK9 and LDL among patients at high cardiovascular risk who had elevated LDL. 

Why this matters

  • Additional therapies are required for patients on statins who are at high risk for cardiovascular events. 

Key results

  • Among patients (n=...